BridgeBio News and Activities

Presence

BridgeBio develops medicines for genetic diseases and some cancers. Its products and services include drug research, clinical development, and rare disease treatments for patients, healthcare providers, and research partners.

BridgeBio products and services overview:

Rare disease drugs
Genetic medicines
Cancer therapies
Clinical development
Drug research

Revenue: ~$230 million

Employees: 900

Headquarters: Palo Alto, United States (USA)

BridgeBio is one of the...

BridgeBio is a company listed under the stock ticker BBIO (US).

Executives

View the org chart displaying its 59 main executives

Most searched biographies at BridgeBio

Popular executive movements at BridgeBio

Maggie Sweeney has joined the company as Senior Director, Clinical Quality and Compliance (posted on May 6 2026).
Julie Miller Everett, who was Chief Business Officer, is promoted to Chief Operating Officer, Skeletal Dysplasias (posted on April 23 2026).
Josh Loehrer who was Chief People Officer, becomes Chief Operating Officer, Cardiovascular (posted on April 23 2026).

Click here to view some more movements at BridgeBio

Create your alert
to follow the executive moves at BridgeBio.

Biotechnology

BridgeBio has 2,415 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
Boundless Bio will change its company name to Serapha Bio on Dec 31, 2026. (posted on June 23 2026).